Krystal Biotech has the GF Score of 58, which implies that the company
might have
Poor future performance potential.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Krystal Biotech
might have
Poor future performance potential.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Krystal Biotech (FRA:4KB) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Krystal Biotech GF Score Related Terms
FRA:4KB vs TECH, SMMT, ARWR: GF Score Comparison
For the Biotechnology subindustry, Krystal Biotech's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krystal Biotech GF Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Krystal Biotech's GF Score distribution charts can be found below:
* The bar in red indicates where Krystal Biotech's GF Score falls into.
Krystal Biotech (FRA:4KB) has a GF Score of 58 as of Jun. 30, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Krystal Biotech and its competitors. This is 71% above median its historical median of 34.00. Over the past decade, Krystal Biotech's GF Score has ranged from 12.00 to 60.00.
Is Krystal Biotech's GF Score too high?
Krystal Biotech's current GF Score of 58 is 71% above median its 10-year median of 34.00. Over the past 10 years, this metric has ranged from a low of 12.00 to a high of 60.00. Overall, Krystal Biotech has a GF Score™ of 58/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Krystal Biotech's GF Score compare to TECH and SMMT?
Krystal Biotech's GF Score of 58 can be compared against companies in the Biotechnology industry. Historically, Krystal Biotech's own GF Score has ranged from 12.00 to 60.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Krystal Biotech and its competitors. Krystal Biotech's current GF Score is 58, which is 71% above median its own 10-year median of 34.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krystal Biotech stock overvalued right now?
Based on GuruFocus' analysis, Krystal Biotech (FRA:4KB) is currently considered Modestly Overvalued. The stock's GF Value™ is €269.18, compared to a current price of €326.30 — trading 21.2% above its estimated fair value. The current GF Score is 58, which is 71% above median its 10-year median of 34.00. Krystal Biotech's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Krystal Biotech (FRA:4KB), the current GF Score is 58 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Krystal Biotech (FRA:4KB) Overvalued in 2026?
Based on GuruFocus' analysis, Krystal Biotech stock appears to be overvalued.
The current stock price of €326.30 is trading 21.2% above its estimated GF Value™ of €269.18.
GuruFocus considers Krystal Biotech to be Modestly Overvalued.
Key valuation signals for FRA:4KB:
GF Score: 58 (71% above median its 10-year median of 34.00)
GF Value™: €269.18 vs. price of €326.30 (21.2% above fair value)
No single metric tells the full story. See the FRA:4KB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
58GF Score
Get the complete analysis for FRA:4KB
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4KB has been successfully added to your 